InterCure Ltd.

Informe acción NasdaqGM:INCR

Capitalización de mercado: US$48.5m

InterCure Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de InterCure.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals14.0%
Tasa de crecimiento de los ingresosn/a
Rentabilidad financiera futuran/a
Cobertura de analistas

None

Última actualizaciónn/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Seeking Alpha • Jun 30

InterCure: A Cannabis Industry Leader Still Flying Under The Radar

Summary InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a positive 2023 ER. The company is entitled to full compensation from the Israeli government for the damage taken. Pharmaceutical Cannabis industry is poised for significant growth in the coming years. InterCure stock should be considered poorly valued. Read the full article on Seeking Alpha
Seeking Alpha • Apr 22

InterCure: Bargain Israel Cannabis Play

Summary InterCure Ltd. has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel, but is expected to recover. The cannabis market in Israel is still limited to medical use, with expansion to medical cannabis patient access to grow the market in 2024. InterCure stock is cheap at only about 1x sales, with catalysts for growth in 2024 and beyond. Read the full article on Seeking Alpha
Seeking Alpha • Sep 06

InterCure: A Leader In Global Cannabis

Summary The global cannabis market will eventually be far bigger than North America. InterCure is a leading company in global pharmaceutical cannabis. Investors can still get in early while most attention is focused elsewhere. InterCure's Chairman is a national hero and former prime minister. Different routes to success in cannabis One of the enjoyable aspects of writing for Seeking Alpha is introducing readers to smaller companies that are taking an unusual and interesting approach to cannabis. These companies are mostly overlooked by analysts and the media, but offer something different -- and potentially profitable -- for the open-minded investor. Every new industry eventually consolidates around a few dominant companies through a process that takes many years. I discussed this in an article titled Trulieve: Why You Must Own This Future Dominant Cannabis Company. However, there is still great potential among other, smaller, companies. Their strategies for success are various, but each one has something that sets them apart. This difference opens an alternative path that may, or may not, lead to success, and makes them worthy of our attention. In this article we will discuss one such company: InterCure, Ltd (INCR). This report draws on a recent interview with InterCure CEO Alex Rabinovitch and a series of emails with Communications Officers Adam Haliva and Ori Mandelabum. Courtesy of Intercure. InterCure: The company InterCure is an Israeli company listed on NASDAQ. Its home cannabis market is 100% pharmaceutical. There has been some discussion of adult use, but due in part to the dysfunctional government in Israel it's still some ways off. Cannabis is very highly regulated. Patients must receive a prescription, and doctors must have a special license to prescribe. Legalization began after decades of research on medical cannabis (THC was first isolated in Israel in 1964), and has grown to the point that Israel, and InterCure in particular, are important players in the global industry ex North America. The global cannabis market Cannabis investors owe it to themselves to learn about the global market. This market will eventually exceed the North American market by several times. In addition, it is currently at a much earlier stage, and has a longer growth runway. Although the global market has its challenges, many of the barriers hindering North American companies are absent. There are no barriers to financial services or uplisting, and no confiscatory 280E taxes. Federal legalization is not paralyzed by special interest politics. Two cannabis legalization models There are two models for legal cannabis. Medical cannabis is the model for North America, with which we are familiar. Cannabis is legalized on a medical basis first. Companies and products are regulated but free to offer cannabis in any form. Eventually cannabis is legalized for adult use, and the two programs exist side by side. The second approach is pharmaceutical cannabis, and it is the model in the entire rest of the world, 40 countries so far and counting. Cannabis is put in the same category as other drugs and supervised by the same regulatory bodies (compare to the US, where the FDA has been mostly silent). It is highly restricted, regulated and monitored from seed to sale. It is much more demanding in terms of expertise and resources than the North American medical model. The endgame is still adult use as liberalizing attitudes and regulation reach their final state, but as it will be regulated by the countries it is expected to be highly regulated too. Companies are willing to take on the extra challenges because of the huge growth potential in a nascent industry. InterCure in Israel InterCure has been building its pharmaceutical cannabis business since 2008. and is the biggest pharma cannabis manufacturer outside of North America. In Israel cannabis can only be sold in special pharmacies, and InterCure has the only chain of cannabis dedicated pharmacies. It is number one in sales in Israel, which has the highest percentage of cannabis users of any country in the world. In a European study cited by Israeli Cannabis Magazine 27% of adult Israelis used it in the past year, and 19% in the past month. The Czech Republic was second in annual use at 11.4% and France was third at 11.3%. The annual use is around 25% in the US according to a YouGov survey, and was 16% in 2018 according to the National Institute of Drug Abuse. 1.3% of Israelis have medical cannabis monthly prescriptions. In the latest earnings call, InterCure's CEO estimates that number will eventually be as high as 5%,which would be 400% market growth. The company clearly has a strong domestic business base. InterCure international strategy InterCure has identified four other core target markets for growth: Germany, UK, Australia, and Austria. In addition, they have high demand for their branded products in other countries, including Switzerland and China. International expansion has been a successful growth strategy for companies based in Israel, with Wix (WIX), Sodastream and Teva (TEVA) being well-known examples. For ambitious companies it's almost essential in a country of only 8.8 million people. InterCure has been building its international capabilities for some years. They are currently number one in pharma cannabis sales in the world. They have six cultivation sites around the world and a supply chain reaching four continents. There are business relationships with a number of companies, including OrganiGram (OGI), Charlotte's Web (CWBHF), Tilray (TLRY), Teva, and Cookies. Cookies is the most powerful cannabis brand in the world, years ahead of anyone else. I encourage readers to look at their website to see why. Intercure Cookies branded store in Beersheva (Courtesy of Intercure.) InterCure's strategy is to replicate the pharmaceutical model they have developed successfully in Israel. Other companies, like Tilray, Canopy Growth (CGC) and Curaleaf (CURLF), are starting to operate in the international arena, but none have InterCure's expertise, experience, or record of success. By getting established early they will be well positioned when countries reach the promised land of adult use. When that happens, the company with the best infrastructure, relationships and brands will be in a powerful position to be one of the dominant companies. InterCure's unique asset InterCure has one additional powerful and unique advantage. The Chairman of the Board is Ehud Barak. To illustrate the impact, imagine that a combination of Colin Powell and Barack Obama became the Chairman of a company like Green Thumb (GTBIF). Mr. Barak is a former Lt. General in the Israeli Defense Forces and the most decorated soldier in Israel's history. He was defense minister and deputy prime minister in several governments. He has also served as Prime Minister of Israel. Mr. Barak is not a figurehead. He has a long time involvement in cannabis and helped InterCure import the first cannabis into Israel after the import ban ended in 2017. Ehud Barak and INCR team at TSX market opening from southern cultivation site. (Courtesy of Intercure.) Risks There are risks with any emerging growth industry company. In InterCure's home market, while there is continuing slow liberalization, the regulatory environment is challenging. In one recent example, when the cannabis licenses for a group of doctors were suspended, it materially harmed the company's results for the quarter. The domestic market is also highly competitive. Everyone wants to do business in a country with the highest proportion of cannabis users in the world. InterCure has demonstrated superior execution so far, to become number one there, and must continue that trend. The international market is also becoming highly competitive, Tilray, Curaleaf, Canopy, and other big firms have moved into the space. InterCure announced Q2 2022 results on August 15 Highlights: Revenue was $37 million [CAD], up 9% sequentially and 100% over Q2 2021. Gross profit was up 16% to $16 million, for a respectable gross margin of 43%. Operations cash flow was positive for the eighth consecutive quarter at $.3 million, and the cash balance is $96 million. Adjusted EBITDA was up 4% sequentially to $9 million, for a relatively low 23% margin. Net income was $6 million, or $0.13 per share.
Seeking Alpha • Aug 15

InterCure reports Q2 results

InterCure press release (NASDAQ:INCR): Q2 net income of $6M, representing a 160% Y/Y growth Revenue of $37M. Adjusted EBITDA increased 90% year-over-year to $9 million, representing 23% of revenues and 4% sequential growth.
Seeking Alpha • Jun 07

InterCure Is Growing In The Massive Global Cannabis Market

Most of cannabis industry growth will occur outside North America. The road to global growth starts with medical cannabis. InterCure is leveraging its expertise to take advantage of domestic and international growth.
Seeking Alpha • Feb 16

IntureCure: Israel Recreation Cannabis Boom On The Way

InterCure provided strong preliminary results for Q4'21. The Israeli company has a major catalyst in the future approval of recreational cannabis in their home country. The stock is cheap trading at less than 3x '22 sales targets with major catalysts ahead.
Seeking Alpha • Nov 08

InterCure Chairman Ehud Barak, CEO Alex Rabinovitch - Israel Cannabis And Beyond (Video)

Recent Nasdaq entrant InterCure is the most profitable cannabis company outside North America. Chairman Ehud Barak, Israel's former Prime Minister, and CEO Alex Rabinovitch discuss Israel's cannabis landscape, Europe's gradual progress and US legalization. Partnerships with companies like Tilray, Cookies and OrganiGram. The importance of fundamentals.
Seeking Alpha • Sep 19

InterCure: Internationally Profitable Cannabis (Podcast Transcript)

InterCure is the most profitable cannabis company outside North America and recently uplisted to Nasdaq. Israel's former Prime Minister, Chairman Ehud Barak and CEO Alex Rabinovitch join the podcast to discuss Israel's cannabis landscape and what investors can expect going forward. Europe's gradual progress, building a strong brand with top international names. Upside remains.
Seeking Alpha • Sep 09

InterCure: Ignored Uplisting

InterCure reported exceptional Q2'21 revenues with numbers up 400% over last year. The Israeli cannabis company recently uplisted to the Nasdaq to limited fanfare. The stock remains cheap at an EV of ~2.5x '22 sales targets, a major discount to Canadian cannabis stocks.

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como InterCure no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:INCR - Estimaciones futuras de los analistas y datos financieros pasados (ILS Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2025270-361317N/A
9/30/2025257-53-33N/A
6/30/2025243-71-19-11N/A
3/31/2025241-69-45-39N/A
12/31/2024239-68-72-67N/A
9/30/2024256-67N/AN/AN/A
6/30/2024273-66N/AN/AN/A
3/31/2024312-61-25-23N/A
12/31/2023356-62-56-54N/A
9/30/2023388-20N/AN/AN/A
6/30/202341521N/AN/AN/A
3/31/202340832-18-4N/A
12/31/2022389453251N/A
9/30/202236333-617N/A
6/30/202232424424N/A
3/31/202227415725N/A
12/31/202122051630N/A
9/30/2021167172032N/A
6/30/2021128201225N/A
3/31/20219413219N/A
12/31/202065-37-138N/A
9/30/202040-63-25-3N/A
6/30/202020-80-42-16N/A
3/31/202011-91-47-13N/A
12/31/20199-6-40-12N/A
9/30/201977N/A-11N/A
6/30/2019518N/A-5N/A
3/31/2019227N/A-3N/A
12/31/2018N/A-13N/A-1N/A
9/30/2018N/A-10N/A-1N/A
6/30/2018N/A-8N/A-1N/A
3/31/2018N/A-7N/A-1N/A
12/31/2017N/A-6N/A-1N/A
9/30/2017N/A-4N/A-1N/A
6/30/2017N/A-2N/A-1N/A
3/31/2017N/A-2N/A-1N/A
12/31/2016N/A0N/A-1N/A
9/30/201600N/A-1N/A
6/30/20160-1N/A-1N/A
3/31/201610N/A-1N/A
12/31/20151-2N/A-2N/A
9/30/20152-1N/A-1N/A
6/30/20153-2N/A-1N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de INCR es superior a la tasa de ahorro (3.5%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de INCR crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de INCR crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de INCR crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de INCR crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de INCR se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/06 07:00
Precio de las acciones al final del día2026/05/06 00:00
Beneficios2025/12/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

InterCure Ltd. está cubierta por 2 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Matt BottomleyCanaccord Genuity
Vivien AzerTD Cowen